YBX1 and colorectal carcinoma: These findings indicate that CD44v6 was able to upregulate YB-1 expression through PGE2 in CRC CICs after FOLFOX therapy (Figure 3D, lanes 4 or 5 vs. lanes 2 or 3), or in FOLFOX resistant SW948-FR CICs (Figure 3D, lane 8 vs. 7).